Back to search

Article

Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab

2024-10-08

Abstract excerpt

Biliary tract cancers demonstrate profound therapeutic resistance, and broadly effective therapies for refractory disease are lacking. We conducted a single-arm, second-line phase II trial combining DKN-01, a humanized monoclonal antibody targeting Dickkopf-1 (DKK-1), and nivolumab to treat patients with advanced biliary tract cancer ( NCT04057365 ). No objective responses were seen. To identify mechanisms of tre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
85a7bba2-7da1-532d-8133-3515950369be
DOI
10.1101/2024.10.08.24315092
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabDOI 10.1101/2024.10.08.24315092
Select a neighboring publication to make it the new centre.